Overseas Network, June 16 The US Food and Drug Administration (FDA) canceled the emergency use right of hydroxychloroquine for the treatment of new coronary pneumonia on the 15th, citing the lack of evidence that the drug is effective in the treatment of new coronary pneumonia. The potential risk is greater.
According to the "New York Post" report, the US Food and Drug Administration said in a statement that hydroxychloroquine and another drug chloroquine (usually used to treat malaria and some severe arthritis) "is unlikely to effectively treat the new crown pneumonia". In addition, in view of the continued side effects that occur after taking these two drugs, the US Food and Drug Administration believes that the potential risks have exceeded the benefits that the drugs can bring.
U.S. Secretary of Health and Human Services Alex Aza said that although the Food and Drug Administration under his supervision has taken this measure, doctors can still prescribe special prescriptions for the use of the drug for individual patients. The order only applies to hospitals and other institutions, not to the interaction between doctors and patients."
In March this year, the US Food and Drug Administration issued an emergency authorization to use the drug to treat new coronary pneumonia. However, several current studies on the drug have shown that it has no effect and cannot prevent infection with the new coronavirus.
